Investors back foodtech startups for GLP-1 users

Venture capitalists are pouring money into food and beverage companies targeting consumers on GLP-1 drugs like Ozempic. These startups are creating products for protein intake, nausea relief, and micronutrient support designed to complement the weight loss medications. This move signals a new wave of essential "supporting cast" products for an exploding market.